Propofol May Hold Key to New Epilepsy Treatments

Strategic Insights -

Researchers at Weill Cornell Medicine and Linköping University have found that the general anesthetic propofol may be used to develop new treatment strategies for epilepsy and other neurological disorders. The study, published in Nature, provides high-resolution structural details of how propofol inhibits the activity of HCN1, an ion channel protein found on many types of neurons. The researchers also discovered that propofol can bind to HCN1 in a way that restores its functionality when it contains certain epilepsy-associated mutations.

Key Takeaways:

  • Propofol, a general anesthetic, may be repurposed to treat epilepsy and other neurological disorders due to its unique mechanism of action on HCN1 ion channels.
  • HCN1 ion channels are found on many types of neurons and play a crucial role in controlling electrical voltage across the cell membrane.
  • The researchers found that propofol inhibits HCN1 activity by binding within a groove between two elements of the channel protein's central pore structure.
  • For two different HCN1 mutations associated with early infantile epileptic encephalopathy (EIEE), propofol restored the mutant channels to normal or near-normal function.
  • The study suggested two possible therapeutic approaches: using propofol directly to treat HCN1-mutation epilepsies or designing modified, non-anesthetic versions of propofol that bind to HCN1 more selectively.
  • The research was supported by the National Institute of General Medical Sciences, the National Institute of Neurological Disorders and Stroke, and the Hartwell Foundation.
  • The study's findings may lead to the development of new therapies for epilepsy and other HCN1-linked disorders.

Statistics:

  • 4 basic forms of HCN ion channels exist in humans: HCN1 to HCN4.
  • HCN1 ion channels are found especially on cells in the heart and nervous system.
  • The researchers used cryo-electron microscopy and other methods to determine the high-resolution structural details of propofol's action on HCN1.
  • The study found that propofol binds to HCN1 with selectivity for HCN1 over other HCNs.
  • Two different HCN1 mutations associated with EIEE were restored to normal or near-normal function by propofol.

Sources:

  • "Researchers at Weill Cornell Medicine and Linköping University" (no specific publication date).
  • "The study, published in Nature" (July 31, 2024).
  • National Institute of General Medical Sciences.
  • National Institute of Neurological Disorders and Stroke.
  • Hartwell Foundation.
  • Weill Cornell Medicine.